Patients who voluntarily participate in the study and have signed a written informed consent form (ICF);

Male patients aged 18 to 75 years (inclusive) at the time of signing the ICF;

Histologically or cytologically confirmed prostate cancer, without prior novel hormonal therapy (NHT) or chemotherapy;

Assessed as having metastatic hormone-sensitive prostate cancer (mHSPC), defined as: histologically or cytologically confirmed prostate cancer with distant metastases (beyond regional lymph nodes) detected by bone scan, MRI, CT, PET/CT, or pathological examination, and who have not received hormonal therapy or chemotherapy;

Eastern Cooperative Oncology Group (ECOG) performance status (PS) ≤ 1;

Normal routine blood count and liver and kidney functions, expected to tolerate treatment for mHSPC;

Expected survival period ≥ 12 weeks.

Agreement to sign the ICF.

Minimum age: 18

Patients who do not meet the inclusion criteria;

Patients currently receiving other systemic anticancer treatments (such as chemotherapy and/or immunotherapy);

Patients who have undergone organ transplantation within the past three months;

Patients with active, known, or suspected autoimmune diseases; or those testing positive for hepatitis B virus, hepatitis C virus, or HIV indicating acute or chronic infection;

Patients with severe life-threatening diseases;

Patients who have not signed the ICF;

Other conditions deemed by the researchers to make the patient unsuitable for participation in the trial.